

10/686,809

1/24/2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/CAPLUS enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 CAPLUS coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change
NEWS 22 DEC 17 USPATOLD added to additional database clusters
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26 DEC 17 MEDLINE and LMEMLINE updated with 2008 MeSH vocabulary
NEWS 27 DEC 17 CA/CAPLUS enhanced with new custom IPC display formats
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available
NEWS 30 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:23:09 ON 24 JAN 2008

=>

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:23:20 ON 24 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JAN 2008 HIGHEST RN 1000668-36-9
DICTIONARY FILE UPDATES: 23 JAN 2008 HIGHEST RN 1000668-36-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10686809_NEW_1242008.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 15:23:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2261 TO ITERATE

100.0% PROCESSED 2261 ITERATIONS 143 ANSWERS
SEARCH TIME: 00.00.01

L2 143 SEA SSS FUL L1

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'MEDLINE' ENTERED AT 15:23:58 ON 24 JAN 2008

FILE 'CAPLUS' ENTERED AT 15:23:58 ON 24 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:23:58 ON 24 JAN 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:23:58 ON 24 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2

SAMPLE SEARCH INITIATED 15:24:02 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED
SEARCH TIME: 00.00.02

43 ITERATIONS

9 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 234 TO 626
PROJECTED ANSWERS: 9 TO 179

L3 185 L2

=> s l3 and (cancer? or tumor?)
L4 58 L3 AND (CANCER? OR TUMOR?)

=> s l4 and angiogenesis
L5 13 L4 AND ANGIOGENESIS

=> s l4 and (multidrug or multi-drug)
L6 15 L4 AND (MULTIDRUG OR MULTI-DRUG)

=> d l6 1-15 ibib, abs, hitstr

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757332 CAPLUS

DOCUMENT NUMBER: 139:276902

TITLE: Preparation of 2-(3-indolyl)-2-oxoacetamide
derivatives as angiogenesis inhibitors and anticancer
agents

INVENTOR(S): Chen, Chiung-tong; Chen, Shu-jen; Hsu, Ming-chu;
Hwang, Der-ren; Li, Wen-tai; Lin, Chu-chung

PATENT ASSIGNEE(S): National Health Research Institutes, Taiwan

SOURCE: U.S. Pat. Appl. Publ., 26 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003181482	A1	20030925	US 2002-310711	20021205
US 6903104	B2	20050607		
US 2005234098	A1	20051020	US 2005-145628	20050606
PRIORITY APPLN. INFO.:			US 2001-337962P	P 20011206
			US 2002-310711	A1 20021205

OTHER SOURCE(S): MARPAT 139:276902
GI




AB This invention relates to novel heteroatom containing compds. [R1 = independently each (un)substituted isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl; R2 = independently H, each (un)substituted C1-10 alkyl or aryl; or R1 and R2 are taken together with the nitrogen atom to which they are attached to form an (un)substituted 5-8 membered ring comprising C, N, S, or O atoms but not to form 4-phenylpiperazin-1-yl, 4-(pyridin-4-yl)piperazin-1-yl, 4-(pyridin-2-yl)piperazin-1-yl, 4-(2-nitrophenyl)piperazin-1-yl, 4-(3,5-dimethoxyphenyl)piperazin-1-yl, or 4-[bis(4-fluorophenyl)methyl]piperazin-1-yl; R3 = independently each (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C4-10 cycloalkenyl, aryl, heteroaryl, or heterocyclyl; R4 = each independently H, NO₂, halo, cyano, R₇, OR₇, CO₂R₇, SR₇, NR₇R₇, C(O)R₇, C(O)NR₇R₇, OC(O)R₇, S(O)R₇, S(O)NR₇R₇, NR₇C(O)NR₇R₇, NR₇C(O)R₇, NR₇(CO₂R₇), NR₇S(O)NR₇R₇, or NR₇S(O)R₇, S(O)R₇; n = 0, 1, 2, 3, or 4; R₇ = independently H, each (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl]. These compds. have potent anticancer, cytotoxic, and anti-angiogenic activity and are useful for the prevention and treatment of diseases, in particular a cancer including a human leukemia, sarcoma, osteosarcoma, lymphoma, melanoma, ovarian, skin, testicular, gastric, pancreatic, renal, breast, prostate colorectal, head and neck, brain, esophageal, bladder, adrenal cortical, lung, bronchus, endometrial, cervical or hepatic cancer, or cancer of unknown primary site. Moreover the cancer is a drug resistance phenotype of which the cancer cells express P-glycoprotein (MDR), multidrug resistance-associated proteins (MRP), lung cancer resistance-associated proteins (LRP), breast cancer resistance proteins (BCRP) or other proteins associated with resistance to anticancer drugs. Thus, a solution of 1.17 g indole 10 mL THF was added dropwise to a suspension of 1.34 g potassium tert-butoxide in 10 mL THF, stirred at room temperature for 2 h, then treated dropwise with a solution of

1.32 g 5-(chloromethyl)-3-methylisoxazole in 5 mL THF, and allowed stand for 4 h, and quenched by adding 10 mL saturated ammonium chloride to give, after workup and silica gel chromatog., 1.61 g 5-(1H-1-indolylmethyl)-3-methylisoxazole (II) (76%). A solution of 212 mg II in 10 mL di-Et ether was added to 254 mg oxalyl chloride dropwise at 0°, stirred at 0° for 3 h, evaporated to remove the solvent, dissolved in 5 mL THF, treated with a solution of 114 mg 3-methyl-5-isothiazolamine and 1 mL Et₃N in 10 mL THF dropwise, stirred for 10 h, and then treated with 1 N NaOH (4 mL) to give, after workup and crystallization, 0.27 g I (R1 = 3-methyl-5-isothiazolyl, R2 = R4 = H, R3 = 3-methyl-5-isoxazolyl) (III) (71%). III in vitro inhibited the growth of human cancer cell lines DLD1, HA-22T, HEP G2, HONE1, HR, and NUGC3 with IC₅₀ of 41, 123, 93, 4, 8, and 12 nM, resp.

IT 501921-65-9P, N-(4-Pyridyl)-2-[1-(4-cyanobenzyl)-1H-indol-3-yl]-2-oxoacetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (3-indolyl)oxoacetamide derivs. as angiogenesis inhibitors and anticancer agents)

RN 501921-65-9 CAPLUS
 CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]-α-oxo-N-4-pyridinyl-
 (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:235682 CAPLUS

DOCUMENT NUMBER: 138:378576

TITLE: Synthesis and Biological Evaluation of N-Heterocyclic Indolyl Glyoxylamides as Orally Active Anticancer Agents

AUTHOR(S): Li, Wen-Tai; Hwang, Der-Ren; Chen, Ching-Ping; Shen, Chien-Wei; Huang, Chen-Long; Chen, Tung-Wei; Lin, Chi-Hung; Chang, Yee-Ling; Chang, Ying-Ying; Lo, Yue-Kan; Tseng, Huan-Yi; Lin, Chu-Chung; Song, Jeng-Shin; Chen, Hua-Chien; Chen, Shu-Jen; Wu, Se-Hui; Chen, Chiung-Tong

CORPORATE SOURCE: Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, 114, Taiwan

SOURCE: Journal of Medicinal Chemistry (2003), 46(9), 1706-1715

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:378576


AB A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compds. studied, N1-(3-Methyl-5-isothiazolyl)-2-[1-[(3-methyl-5-isoxazolyl)methyl]-1H-3-indolyl]-2-oxoacetamide (I) showed the most potent activity of growth inhibition (IC50 = 17-1711 nM) in several human cancer cells. Given orally, compds. I and N1-(3-Methyl-5-isothiazolyl)-2-[1-(4-cyanobenzyl)-1H-3-indolyl]-2-oxoacetamide dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.

IT 528593-64-8P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and biol. evaluation of N-Heterocyclic indolyl glyoxylamides as orally active anticancer agents in relation to apoptosis induction and partition coefficient)

RN 528593-64-8 CAPLUS
 CN 1H-Indole-3-acetamide, 1-(2-furanylmethyl)- α -oxo-N-4-pyridinyl- (CA
 INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:221515 CAPLUS

DOCUMENT NUMBER: 138:238008

TITLE: Preparation of 3-glyoxylamide indoles as anticancer
 agents useful against multidrug-resistant
 cancer cells

INVENTOR(S): Koya, Keizo; Sun, Lijun; Ono, Mitsunori; Liang,
 Guiqing; James, David; Li, Hao; Xia, Zhi-Qiang

PATENT ASSIGNEE(S): SBR Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022280	A2	20030320	WO 2002-US27513	20020828
WO 2003022280	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460347	A1	20030320	CA 2002-2460347	20020828
AU 2002323474	A1	20030324	AU 2002-323474	20020828
EP 1427416	A2	20040616	EP 2002-757457	20020828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504790	T	20050217	JP 2003-526409	20020828
US 2003092751	A1	20030515	US 2002-232394	20020829
US 6958348	B2	20051025		
US 2006004044	A1	20060105	US 2005-136074	20050524

PRIORITY APPLN. INFO.:

US 2001-322022P

P 20010913

WO 2002-US27513

W 20020828


US 2002-232394

A1 20020829

OTHER SOURCE(S):

MARPAT 138:238008

GI



AB The anti-cancer compound has a structural formula I wherein Z1 and Z2 are independently O, S, NOR5 or NR5, and R1-R5 are H, aliphatic group, aryl group or other specifically defined groups. Thus, 2-(1-(4-chloro-benzyl)-1-indo-3-yl)-N-(3-methyl-isothiazol-5-yl)-2-oxo-acetamide was prepared from oxylyl chloride 5.1 mmol, 1-(4'-chlorobenzyl)-indole (4.14 mmol) and 5-amino-3-methylisothiazole (9.73 mmol), and demonstrated significantly high anti-cancer activity (IC50 0.0005 μ M) against five cancer lines with wide variety of multidrug-resistant cancer cell types (MDA 435, HL 60, DU 146, MES SA, and H2).


IT 501921-60-4P 501921-65-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glyoxylamide indoles as anticancer agents useful against multidrug-resistant cancer cells)


RN 501921-60-4 CAPLUS

CN 1H-Indole-3-acetamide, N-[5-(aminocarbonyl)-2-pyridinyl]-1-[(4-chlorophenyl)methyl]- α -oxo- (CA INDEX NAME)



RN 501921-65-9 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:915607 CAPLUS

DOCUMENT NUMBER: 136:193482

TITLE: New small-molecule tubulin inhibitors

AUTHOR(S): Bacher, G.; Beckers, T.; Emig, P.; Klenner, T.;
Kutschert, B.; Nickel, B.

CORPORATE SOURCE: IUPAC Commission, Research & Development Oncology,
ASTA Medica AG, Frankfurt, 60314, Germany

SOURCE: Pure and Applied Chemistry (2001), 73(9), 1459-1464
CODEN: PACHAS; ISSN: 0033-4545

PUBLISHER: International Union of Pure and Applied Chemistry

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review. The variety of biol. agents directed toward the tubulin system exceeds those acting on DNA, making it an important target for cancer chemotherapy. However, the complicated chemical structures and restricted access to the natural resources, in combination with the development of drug resistance, limit the first generation of natural products. Considerable efforts in the search and synthesis of new synthetic compds., such as small mol. tubulin inhibitors, gave access to novel potential/promising drugs. Among these substances, two series of novel, easily accessible indole classes were identified as tubulin-destabilizing agents. Owing to the synthetic nature, potent in vitro and in vivo antitumoral activity, and efficacy against multidrug-resistant (MDR) tumors, D-24851 and D-64131 have significant potential in cancer treatment.

IT 204205-90-3, D-24851

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (small-mol. tubulin inhibitors)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:58000 CAPLUS

DOCUMENT NUMBER: 134:290069

TITLE: D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

AUTHOR(S): Bacher, Gerald; Nickel, Bernd; Emig, Peter; Vanhoefer, Udo; Seeber, Siegfried; Shandra, Alexei; Klenner, Thomas; Beckers, Thomas

CORPORATE SOURCE: Department of Cancer Research, ASTA Medica AG, Frankfurt am Main, 60314, Germany

SOURCE: Cancer Research (2001), 61(1), 392-399

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB N-(pyridin-4-yl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide (D-24851) is a novel synthetic compound that was identified in a cell-based screening assay to discover cytotoxic drugs. D-24851 destabilizes microtubules and blocks cell cycle transition specifically at G2-M phase. The binding site of D-24851 does not overlap with the tubulin binding sites of known microtubule-destabilizing agents like vincristine or colchicine. In vitro, D-24851 has potent cytotoxic activity toward a panel of established human tumor cell lines including SKOV3 ovarian cancer, U87 glioblastoma, and ASPC-1 pancreatic cancer cells. In vivo, oral D-24851 treatment induced complete tumor regressions (cures) in rats bearing Yoshida AH13 sarcomas. Of importance is that the administration of curative doses of D-24851 to the animals revealed no systemic toxicity in terms of body weight loss and neurotoxicity in contrast to the administration of paclitaxel or vincristine. Interestingly, multidrug-resistant cell lines generated by vincristine-driven selection or transfection with the Mr 170,000 P-glycoprotein encoding cDNA were rendered resistant toward paclitaxel, vincristine, or doxorubicin but not towards D-24851 when compared with the parental cells. Because of its synthetic nature, its oral applicability, its potent in vitro and in vivo antitumoral activity, its efficacy against multidrug-resistant tumors, and the lack of neurotoxicity, D-24851 may have significant potential for the treatment of various malignancies.


IT 204205-90-3, D 24851

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:169455 USPATFULL

TITLE: Combination bacteriolytic therapy for the treatment of tumors

INVENTOR(S): Dang, Long, Baltimore, MD, UNITED STATES
Bettegowda, Chetan, Baltimore, MD, UNITED STATES
Kenzler, Kenneth W., Bel Air, MD, UNITED STATES
Vogelstein, Bert, Baltimore, MD, UNITED STATES

PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, UNITED STATES, 21218 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007148135	A1	20070628
APPLICATION INFO.:	US 2004-568765	A1	20041021 (10)
	WO 2004-US34625		20041021
			20070212 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-512923P	20031022 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, LTD., 1100 13th STREET, N.W., SUITE 1200, WASHINGTON, DC, 20005-4051, US	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	1016	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous

injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D-24851

(combination bacteriolytic therapy for the treatment of tumors using spores of anaerobic bacteria and microtubule agents)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



L6 ANSWER 7 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2006:167882 USPATFULL

TITLE: Bis(thio-hydrazide amides) for treatment of hyperplasia

INVENTOR(S): Sherman, Matthew L., Newton, MA, UNITED STATES

Vaghefi, Farid, Burlington, MA, UNITED STATES

Chen, Lan Bo, Lexington, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006142393	A1	20060629
APPLICATION INFO.:	US 2005-226929	A1	20050914 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-610270P	20040916 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and medical devices for treating a proliferative disorder in a subject, e.g., restenosis in a blood vessel that has been implanted with a stent, employ a bis(thio-hydrazide amide) represented by Structural Formula I or a pharmaceutically acceptable salt or solvate thereof. ##STR1## Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group.

R.sub.1-R.sub.4 are independently --H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R.sub.1 and R.sub.3 taken together with the carbon and nitrogen atoms to which they

are bonded, and/or R.sub.2 and R.sub.4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.

R.sub.7-R.sub.8 are independently --H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, Nascapine

(bis(thiohydrazide amides) for treatment of hyperplasia)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



L6 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2006:130825 USPATFULL

TITLE: Nanoparticulate compositions of tubulin inhibitor compounds

INVENTOR(S): Papadopoulos, Pavlos, Antioch, IL, UNITED STATES
Raab, Gerhard, Ronneburg, GERMANY, FEDERAL REPUBLIC OF
Doty, Mark J., Grayslake, IL, UNITED STATES
Kipp, James E., Wauconda, IL, UNITED STATES
Roessler, Berthold, Halle/Westfalen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006110462	A1	20060525
APPLICATION INFO.:	US 2005-266518	A1	20051103 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-626036P	20041108 (60)
	US 2005-642878P	20050111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Baxter Healthcare Corporation, One Baxter Parkway - DF3-2E, Deerfield, IL, 60015, US	
NUMBER OF CLAIMS:	78	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2388	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably

N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as "Indibulin," and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D 24851

(Indibulin; particulate compns. of tubulin inhibitors for treatment of resistant cancers and other diseases)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



IT 204205-78-7 204205-80-1 204205-81-2

204205-82-3 204205-85-6 204205-86-7

204205-87-8 204205-91-4 204205-92-5

204205-93-6 204205-95-8 204205-96-9


204205-97-0 204205-98-1 204206-01-9

204206-02-0 204206-03-1

(particulate compns. of tubulin inhibitors for treatment of resistant cancers and other diseases)


RN 204205-78-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL


CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- α -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-87-8 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 204205-91-4 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-93-6 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-98-1 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204206-02-0 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-hydroxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204206-03-1 USPATFULL
 CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2006:4585 USPATFULL
 TITLE: 3-glyoxylamideindoles for treating cancer
 INVENTOR(S): Koya, Keizo, Brookline, MA, UNITED STATES
 Sun, Lijun, Harvard, MA, UNITED STATES
 Ono, Mitsunori, Lexington, MA, UNITED STATES

PATENT ASSIGNEE(S): Liang, Guiqing, Concord, MA, UNITED STATES
James, David, Cambridge, MA, UNITED STATES
Li, Hao, Brookline, MA, UNITED STATES
Xia, Zhi-Qiang, Dedham, MA, UNITED STATES
Synta Pharmaceuticals Corp., Lexington, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006004044	A1	20060105
APPLICATION INFO.:	US 2005-136074	A1	20050524 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-232394, filed on 29 Aug 2002, GRANTED, Pat. No. US 6958348		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-322022P	20010913 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1-20	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1010	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Disclosed is an anti-cancer compound represented by Structural Formula (I): ##STR1## The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-60-4P 501921-65-9P
(preparation of glyoxylamide indoles as anticancer agents useful against multidrug-resistant cancer cells)


RN 501921-60-4 USPATFULL

CN 1H-Indole-3-acetamide, N-[5-(aminocarbonyl)-2-pyridinyl]-1-[(4-chlorophenyl)methyl]- α -oxo- (CA INDEX NAME)



RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)



L6 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:268778 USPATFULL
TITLE: Novel compounds and methods of use thereof
INVENTOR(S): Chen, Chiung-Tong, Taipei, TAIWAN, PROVINCE OF CHINA
Chen, Shu-Jen, Taipei, TAIWAN, PROVINCE OF CHINA
Hsu, Ming-Chu, Taipei, TAIWAN, PROVINCE OF CHINA
Hwang, Der-Ren, Taipei, TAIWAN, PROVINCE OF CHINA
Li, Wen-Tai, Taipei, TAIWAN, PROVINCE OF CHINA
Lin, Chu-Chung, Taipei, TAIWAN, PROVINCE OF CHINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005234098	A1	20051020
APPLICATION INFO.:	US 2005-145628	A1	20050606 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-310711, filed on 5 Dec 2002, GRANTED, Pat. No. US 6903104		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337962P	20011206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1-37	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2031	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel heteroatom containing compounds and compositions thereof, and their use for the prevention and treatment of disease. The invention also provides for methods of making the compounds. The invention is based on the discovery that certain heteroatom containing compounds, 3-oxoacetamideindolyl compounds, have potent anticancer, cytotoxic, and anti-angiogenic activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-65-9P, N-(4-Pyridyl)-2-[1-(4-cyanobenzyl)-1H-indol-3-yl]-2-oxoacetamide

(preparation of (3-indolyl)oxoacetamide derivs. as angiogenesis inhibitors and anticancer agents)

RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)



L6 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:171786 USPATFULL

TITLE: IAP nucleobase oligomers and oligomeric complexes and uses thereof

INVENTOR(S): LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005148535	A1	20050707
APPLICATION INFO.:	US 2004-975974	A1	20041028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516192P	20031030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	3022	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D 24851

(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



L6 ANSWER 12 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:221896 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

INVENTOR(S): Nickel, Bernd, Muhltal, GERMANY, FEDERAL REPUBLIC OF
Bacher, Gerald, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
Klenner, Thomas, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Beckers, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF

Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF
Engel, Jurgen, Alzenau, GERMANY, FEDERAL REPUBLIC OF
Bruyneel, Erik, Harelbeke, BELGIUM
Kamp, Gunter, Munster, GERMANY, FEDERAL REPUBLIC OF
Peters, Kirsten, Munster, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Baxter Healthcare SA, Wallisellen, SWITZERLAND
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171668	A1	20040902
APPLICATION INFO.:	US 2003-686809	A1	20031017 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-492531, filed on 27 Jan 2000, GRANTED, Pat. No. US 6693119		
	Continuation-in-part of Ser. No. US 1999-285058, filed on 2 Apr 1999, GRANTED, Pat. No. US 6232327		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19946301	19990828
	DE 1998-19814838	19980402
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102	

NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I: ##STR1##

and to pharmaceutical compositions having antitumor action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 204205-78-7P 204205-79-8P 204205-80-1P

204205-81-2P 204205-82-3P 204205-85-6P
 204205-86-7P 204205-87-8P 204205-90-3P
 204205-91-4P 204205-92-5P 204205-93-6P
 204205-95-8P 204205-96-9P 204205-97-0P
 204206-01-9P 204206-03-1P 245661-24-9P
 245661-25-0P 245661-26-1P 245661-28-3P
 245661-29-4P 245661-30-7P 245661-31-8P
 245661-38-5P 245661-39-6P 245661-41-0P
 245661-42-1P 245661-43-2P 245661-47-6P
 245661-48-7P 245661-49-8P 245661-50-1P
 245661-51-2P 245661-52-3P 245661-53-4P
 245661-54-5P 245661-55-6P

(preparation of indolylglyoxylamides as antitumor agents)


RN 204205-78-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-79-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-methyl- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-α-oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-87-8 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-93-6 USPATFULL


CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 204205-95-8 USPATFULL
 CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)



RN 204205-96-9 USPATFULL
 CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL
 CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)




RN 245661-28-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)




RN 245661-29-4 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-30-7 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-α-oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL
 CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo- (CA INDEX NAME)




RN 245661-38-5 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245661-39-6 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-41-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 245661-48-7 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 204205-90-3
 CMF C22 H16 Cl N3 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 245661-49-8 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-50-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-[[4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)-α-oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L6 ANSWER 13 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:258429 USPATFULL

TITLE: Novel compounds and methods of use thereof

INVENTOR(S): Chen, Chiung-Tong, Taipei, TAIWAN, PROVINCE OF CHINA

Chen, Shu-Jen, Taipei, TAIWAN, PROVINCE OF CHINA

Hsu, Ming-Chu, Taipei, TAIWAN, PROVINCE OF CHINA

Hwang, Der-Ren, Taipei, TAIWAN, PROVINCE OF CHINA

Li, Wen-Tai, Taipei, TAIWAN, PROVINCE OF CHINA

Lin, Chu-Chung, Taipei, TAIWAN, PROVINCE OF CHINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181482	A1	20030925
	US 6903104	B2	20050607
APPLICATION INFO.:	US 2002-310711	A1	20021205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337962P	20011206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JEFFREY D. HSI, Fish & Richarson P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2068	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel heteroatom containing compounds and compositions thereof, and their use for the prevention and treatment of disease. The invention also provides for methods of making the compounds. The invention is based on the discovery that certain heteroatom containing compounds, 3-oxoacetamideindolyl compounds, have potent anticancer, cytotoxic, and anti-angiogenic activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-65-9P, N-(4-Pyridyl)-2-[1-(4-cyanobenzyl)-1H-indol-3-yl]-2-oxoacetamide

(preparation of (3-indolyl)oxoacetamide derivs. as angiogenesis inhibitors and anticancer agents)

RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)



L6 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:166653 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

INVENTOR(S): Nickel, Bernd, Muhltal, GERMANY, FEDERAL REPUBLIC OF
 Bacher, Gerald, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
 Klenner, Thomas, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
 Beckers, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF
 Engel, Jurgen, Alzenau, GERMANY, FEDERAL REPUBLIC OF
 Bruyneel, Erik, Harelbeke, BELGIUM
 Kamp, Gunter, Munster, GERMANY, FEDERAL REPUBLIC OF
 Peters, Kirsten, Munster, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114511	A1	20030619
	US 6693119	B2	20040217
APPLICATION INFO.:	US 2000-492531	A1	20000127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402
	DE 1999-19946301	19990928
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	576	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The object of the invention is then to widen the field of use of N-substituted indole-3-glyoxylamides and thus to enrich the available pharmaceutical wealth. The possibility of a lower, longer-lasting and better-tolerable medication for the class of substances having antitumor action described in German Patent Application 19814 838.0 should thus be opened up. In particular, the disadvantageous development of resistance, as is known of many antitumor agents, should be circumvented.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 204205-78-7P 204205-79-8P 204205-80-1P
 204205-81-2P 204205-82-3P 204205-85-6P
 204205-86-7P 204205-87-8P 204205-90-3P

204205-91-4P 204205-92-5P 204205-93-6P
 204205-95-8P 204205-96-9P 204205-97-0P
 204206-01-9P 204206-03-1P 245661-24-9P
 245661-25-0P 245661-26-1P 245661-28-3P
 245661-29-4P 245661-30-7P 245661-31-8P
 245661-38-5P 245661-39-6P 245661-41-0P
 245661-42-1P 245661-43-2P 245661-47-6P
 245661-48-7P 245661-49-8P 245661-50-1P
 245661-51-2P 245661-52-3P 245661-53-4P
 245661-54-5P 245661-55-6P

(preparation of indolylglyoxylamides as antitumor agents)


RN 204205-78-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-79-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-methyl- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA
 INDEX NAME)




RN 204205-82-3 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-3-
 pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL
 CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-
 α -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA
 INDEX NAME)




RN 204205-87-8 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(3-pyridinylmethyl)-
 (CA INDEX NAME)




RN 204205-90-3 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-93-6 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 204205-95-8 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL
 CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl-
(CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-
 α -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-
 α -oxo- (CA INDEX NAME)




RN 245661-38-5 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245661-39-6 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester
 (9CI) (CA INDEX NAME)




RN 245661-41-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 245661-48-7 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 204205-90-3
 CMF C22 H16 Cl N3 O2 .




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 245661-49-8 USPATFULL
CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-50-1 USPATFULL
CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL
CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide, α-oxo-N-4-pyridinyl-1-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)-α-oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



L6 ANSWER 15 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2003:134662 USPATFULL
 TITLE: 3-glyoxylamideindoles for treating cancer
 INVENTOR(S): Koya, Keizo, Brookline, MA, UNITED STATES
 Sun, Lijun, Harvard, MA, UNITED STATES
 Ono, Mitsunori, Lexington, MA, UNITED STATES
 Liang, Guiqing, Concord, MA, UNITED STATES
 James, David, Cambridge, MA, UNITED STATES
 Li, Hao, Brookline, MA, UNITED STATES
 Xia, Zhi-Qiang, Dedham, MA, UNITED STATES
 PATENT ASSIGNEE(S): SBR Pharmaceuticals Corp., Lexington, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092751	A1	20030515
	US 6958348	B2	20051025
APPLICATION INFO.:	US 2002-232394	A1	20020829 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-322022P	20010913 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 1151

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is an anti-cancer compound represented by Structural Formula (I): ##STR1##

The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-60-4P 501921-65-9P

(preparation of glyoxylamide indoles as anticancer agents useful against multidrug-resistant cancer cells)


RN 501921-60-4 USPATFULL

CN 1H-Indole-3-acetamide, N-[5-(aminocarbonyl)-2-pyridinyl]-1-[(4-chlorophenyl)methyl]- α -oxo- (CA INDEX NAME)



RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:23:09 ON 24 JAN 2008)

FILE 'REGISTRY' ENTERED AT 15:23:20 ON 24 JAN 2008

L1 STRUCTURE UPLOADED

L2 143 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:23:58 ON 24 JAN 2008

L3 185 S L2

L4 58 S L3 AND (CANCER? OR TUMOR?)

L5 13 S L4 AND ANGIOGENESIS

L6 15 S L4 AND (MULTIDRUG OR MULTI-DRUG)

=> s l4 not py>2000

L7 1 L4 NOT PY>2000

=> d l7 ibib, abs, hitstr

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:814353 CAPLUS

DOCUMENT NUMBER: 133:359224

TITLE: Fatty acid-N-substituted indol-3-glyoxylamide compositions as antitumor agents

INVENTOR(S): Bradley, Matthews O.; Swindell, Charles S.; Anthony, Forrest; Webb, Nigel L.; Fisher, Mark

PATENT ASSIGNEE(S): Protarga, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000067802	A1	20001116	WO 2000-US12752	20000510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000048342	A	20001121	AU 2000-48342	20000510
PRIORITY APPLN. INFO.:			US 1999-133292P	P 19990510
			WO 2000-US12752	W 20000510
OTHER SOURCE(S):		MARPAT 133:359224		
GI				



I

AB The present invention pertains to N-substituted indol-3-glyoxylamides that are conjugates of fatty acids and conjugates of I. The conjugates are useful in treating cancer. In an example taxoprexin completely eliminated all measureable tumors in 7 out of 8 mice at 120 mg/kg/day for 5 days while paclitaxel retarded tumor growth for about 4 days.


IT 204205-90-3D, conjugates, with antitumor agents

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fatty acid-N-substituted indol-3-glyoxylamide compns. as antitumor agents)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:23:09 ON 24 JAN 2008)

FILE 'REGISTRY' ENTERED AT 15:23:20 ON 24 JAN 2008

L1 STRUCTURE UPLOADED

L2 143 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:23:58 ON 24 JAN 2008

L3 185 S L2

L4 58 S L3 AND (CANCER? OR TUMOR?)
L5 13 S L4 AND ANGIOGENESIS
L6 15 S L4 AND (MULTIDRUG OR MULTI-DRUG)
L7 1 S L4 NOT PY>2000

=> s l3 not py>2000

L8 14 L3 NOT PY>2000

=> d l8 1-14 ibib, abs, hitstr

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:30560 CAPLUS

DOCUMENT NUMBER: 134:221365

TITLE: The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways

AUTHOR(S): Schmidt, Dunja T.; Watson, Nikki; Dent, Gordon; Ruhlmann, Elke; Branscheid, Detlev; Magnussen, Helgo; Rabe, Klaus F.

CORPORATE SOURCE: Department of Pulmonology, Leiden University Medical Centre, Leiden, NL-2333 ZA, Neth.

SOURCE: British Journal of Pharmacology (2000), 131(8), 1607-1618

CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE) block allergen-induced contraction of passively sensitized human airways in vitro by a dual mechanism involving a direct relaxant effect on smooth muscle and inhibition of histamine and cysteinyl leukotriene (LT) release from airways. We investigated the effects of non-selective PDE inhibitors and selective inhibitors of PDE3 and PDE4 in order to determine the involvement of PDE isoenzymes in the suppression of allergic bronchoconstriction. Macroscopically normal airways from 76 patients were sensitized with IgE-rich sera (>250 u ml⁻¹) containing specific antibodies against allergen (*Dermatophagoides farinae*). Contractile responses of bronchial rings were assessed using standard organ bath techniques. Passive sensitization caused increased contractile responses to allergen, histamine and LTC₄. Non-selective PDE inhibitors (theophylline, 3-isobutyl-1-methylxanthine [IBMX]), a PDE3-selective inhibitor (motapizone), PDE4-selective inhibitors (RP73401, rolipram, AWD 12-281) and a mixed PDE3/4 inhibitor (zardaverine) all significantly relaxed inherent bronchial tone at resting tension and to a similar degree. Theophylline, IBMX, zardaverine and the combination of motapizone and RP73401 inhibited the contractile responses to allergen and LTC₄. Pre-treatment with motapizone, RP73401, rolipram or the methylxanthine adenosine receptor antagonist, 8-phenyltheophylline, did not significantly decrease responses to either allergen or LTC₄. We conclude that combined inhibition of PDE3 and PDE4, but not selective inhibition of either isoenzyme or antagonism of adenosine receptors, is effective in suppressing allergen-induced contractions of passively sensitized human airways. The relationship between allergen- and LTC₄-induced responses suggests that PDE inhibitors with PDE3 and PDE4 selectivity are likely to act in part through inhibition of mediator release and not simply through direct relaxant actions on airway smooth muscle.

IT 257892-33-4, AWD 12-281


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(phosphodiesterase inhibitors in allergen- and leukotriene C4-induced contractions in sensitized human airways)

RN 257892-33-4 CAPLUS

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-

fluorophenyl)methyl]-5-hydroxy- α -oxo- (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:814353 CAPLUS

DOCUMENT NUMBER: 133:359224

TITLE: Fatty acid-N-substituted indol-3-glyoxylamide compositions as antitumor agents

INVENTOR(S): Bradley, Matthews O.; Swindell, Charles S.; Anthony, Forrest; Webb, Nigel L.; Fisher, Mark

PATENT ASSIGNEE(S): Protarga, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067802	A1	20001116	WO 2000-US12752	20000510
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000048342	A	20001121	AU 2000-48342	20000510
PRIORITY APPLN. INFO.:			US 1999-133292P	P 19990510
			WO 2000-US12752	W 20000510

OTHER SOURCE(S): MARPAT 133:359224

GI




I

AB The present invention pertains to N-substituted indol-3-glyoxylamides that are conjugates of fatty acids and conjugates of I. The conjugates are useful in treating cancer. In an example taxoprexin completely eliminated all measureable tumors in 7 out of 8 mice at 120 mg/kg/day for 5 days while paclitaxel retarded tumor growth for about 4 days.

IT 204205-90-3D, conjugates, with antitumor agents
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fatty acid-N-substituted indol-3-glyoxylamide compns. as antitumor agents)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:55462 CAPLUS

DOCUMENT NUMBER: 132:202635

TITLE: A peptidic binding site model for PDE 4 inhibitors

AUTHOR(S): Polymeropoulos, Emmanuel E.; Hofgen, Norbert

CORPORATE SOURCE: Department of Chemical Research, Corporate R and D
 ASTA Medica Group, Frankfurt, D-60314, Germany

SOURCE: Quantitative Structure-Activity Relationships (1999),
 18(6), 543-547
 CODEN: QSARDI; ISSN: 0931-8771

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The pseudoreceptor modeling program PrGen was used to construct a peptidic binding site model for phosphodiesterase 4 inhibitors. A training set of 21 diverse compds. (rolipram, nitraquazone and xanthine derivs., imidazo pyrido pyrazinones and 5-oxyindoles) was used to construct the binding site surrogate consisting of five amino acid residues, a Zn⁺² cofactor and an envelope of charged virtual particles. The model was validated by predicting the free energies of binding ΔG_{pred0} of ten ligands (rolipram, imidazo pyrido pyrazinones and 5-oxyindoles). In seven cases the prediction was satisfactory. The rms deviation [4] in ΔG_0 is 0.16 and 1.82 kcal/mol-resulting in an uncertainty in IC₅₀ (or K_i) of 1.32 and 22.81-for the training and the test set resp., while the corresponding maximal prediction errors in ΔG_{pred0} were 0.27 kcal/mol and 4.50 kcal/mol.

IT 204206-02-0 247584-23-2 247584-24-3
247584-27-6 247584-34-5 257892-33-4
260265-54-1 260265-55-2 260265-56-3
260265-57-4 260265-58-5 260265-59-6

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peptidic binding site model for PDE 4 inhibitors)


RN 204206-02-0 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-hydroxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 247584-23-2 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(2,6-difluorophenyl)methyl]-5-hydroxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 247584-24-3 CAPLUS

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(2,6-difluorophenyl)methyl]-5-hydroxy- α -oxo- (CA INDEX NAME)




RN 247584-27-6 CAPLUS

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-1-(1-methylethyl)-α-oxo- (CA INDEX NAME)




RN 247584-34-5 CAPLUS

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-methoxy-α-oxo- (CA INDEX NAME)




RN 257892-33-4 CAPLUS


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy-α-oxo- (CA INDEX NAME)




RN 260265-54-1 CAPLUS
 CN 1H-Indole-3-acetamide, N-(2,6-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy-α-oxo- (CA INDEX NAME)




RN 260265-55-2 CAPLUS
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-methoxy-1-(1-methylethyl)-α-oxo- (CA INDEX NAME)




RN 260265-56-3 CAPLUS
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-methoxy-1-[(3-nitrophenyl)methyl]-α-oxo- (CA INDEX NAME)




RN 260265-57-4 CAPLUS
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-1-[(3-nitrophenyl)methyl]-α-oxo- (CA INDEX NAME)



RN 260265-58-5 CAPLUS
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(2,6-difluorophenyl)methyl]-5-methoxy-α-oxo- (CA INDEX NAME)



RN 260265-59-6 CAPLUS
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-methoxy-α-oxo-1-propyl- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:647583 CAPLUS

DOCUMENT NUMBER: 132:145941

TITLE: Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases

AUTHOR(S): Crocker, I. Caroline; Townley, Robert G.

CORPORATE SOURCE: Creighton University Allergic Disease Center, Omaha, NE, USA

SOURCE: Drugs of Today (1999), 35(7), 519-535

CODEN: MDACAP; ISSN: 0025-7656

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 137 refs. CAMP is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concns. have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclin. animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.


IT 257892-33-4, AWD 12-281

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases)

RN 257892-33-4 CAPLUS

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- α -oxo- (CA INDEX NAME)



REFERENCE COUNT: 137 THERE ARE 137 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 6 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 7 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 8 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 9 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 10 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 11 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 12 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 13 OF 14 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 14 OF 14 USPATFULL on STN
ACCESSION NUMBER: 1999:170623 USPATFULL
TITLE: N-substituted indole-3 glyoxylamides having
anti-asthmatic antiallergic and
immunosuppressant/immuno-modulating action
INVENTOR(S): Lebaut, Guillaume, Saint Sebastien/Loire, France
Menciu, Cecilia, Nantes, France
Kutscher, Bernhard, Maintal, Germany, Federal Republic
of
Emig, Peter, Bruchkobel, Germany, Federal Republic of
Szelenyi, Stefan, Schwaig, Germany, Federal Republic of
Brune, Kay, Marloffstein/Rathsberg, Germany, Federal
Republic of
PATENT ASSIGNEE(S): ASTA Medica Aktiengesellschaft, Germany, Federal
Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6008231		19991228
APPLICATION INFO.:	US 1997-925326		19970908 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19636150	19960906
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Oswecki, Jane C.	
LEGAL REPRESENTATIVE:	Pillsbury Madison & Sutro	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	942	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel N-substituted indole-3-glyoxylamides, to processes for their preparation and to their pharmaceutical use. The compounds have antiasthmatic, antiallergic and immuno-suppressant/immunomodulating actions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-79-8P 204205-80-1P
 204205-81-2P 204205-82-3P 204205-85-6P
 204205-86-7P 204205-87-8P 204205-90-3P
 204205-91-4P 204205-92-5P 204205-93-6P
 204205-95-8P 204205-96-9P 204205-97-0P
 204205-98-1P 204206-01-9P 204206-02-0P
 204206-03-1P

(preparation of N-substituted indoleglyoxylamides as antiasthmatics, antiallergic agents and immunosuppressants/immunomodulators)


RN 204205-78-7 USPTFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-79-8 USPTFULL


CN 1H-Indole-3-acetamide, 1-methyl- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL
 CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- α -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-87-8 USPATFULL
 CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 204205-90-3 USPATFULL
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- α -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-93-6 USPATFULL

CN 1H-Indole-3-acetamide, α -oxo-N-4-pyridinyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-98-1 USPTAFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPTAFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-02-0 USPTAFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-hydroxy- α -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204206-03-1 USPATFULL
 CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



=> FIL STNGUIDE
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
191.92	370.49

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-8.00	-8.00

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 15:37:00 ON 24 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Jan 11, 2008 (20080111/UP).

=> d his

(FILE 'HOME' ENTERED AT 15:23:09 ON 24 JAN 2008)

FILE 'REGISTRY' ENTERED AT 15:23:20 ON 24 JAN 2008

L1 STRUCTURE UPLOADED
 L2 143 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:23:58 ON 24 JAN

2008

L3	185 S L2
L4	58 S L3 AND (CANCER? OR TUMOR?)
L5	13 S L4 AND ANGIOGENESIS
L6	15 S L4 AND (MULTIDRUG OR MULTI-DRUG)
L7	1 S L4 NOT PY>2000
L8	14 S L3 NOT PY>2000

FILE 'STNGUIDE' ENTERED AT 15:37:00 ON 24 JAN 2008